Usefulness of mycophenolate mofetil in Indian patients with C3 glomerulopathy

Joyita Bharati1,*, Karalanglin Tiewsoh2,*, Ashwani Kumar3, Ritambhra Nada3,*, Manish Rathi1, Krishan Lal Gupta1, Harbir Singh Kohli1, Vivekananda Jha1 and Raja Ramachandran1,*

1Department of Nephrology, Post Graduate Institute of Medical Education and Research, Chandigarh, India, 2Department of Pediatrics, Post Graduate Institute of Medical Education and Research, Chandigarh, India and 3Department of Histopathology, Post Graduate Institute of Medical Education and Research, Chandigarh, India

Correspondence and offprint requests to: Raja Ramachandran; E-mail: drraja_1980@yahoo.co.in, Ritambhra Nada; E-mail: ritamduseja@yahoo.com

*These authors contributed equally to this work.

ABSTRACT

Background. C3 glomerulopathy (C3G) is a heterogeneous disease caused by alternative complement pathway abnormalities without any standardized treatment. An immunosuppressive agent, mycophenolate mofetil (MMF), has been recently shown to be useful in treating C3G, mainly in studies from the west. We report the clinical outcome of 17 Indian C3G patients treated with MMF with or without steroids.

Methods. The clinical and histology details of the C3G patients treated with MMF for at least 6 months with a follow-up of at least 12 months were retrieved from the medical records of our center.

Results. The median serum creatinine and proteinuria at presentation were 0.8 mg/dL and 3.7 g/day, respectively, with the majority (88.2%) presenting as nephrotic syndrome. The mean dose of MMF was 1.65 (±0.56) g/day, and the median duration of MMF therapy was 18 months. Two-thirds (64%) of the patients responded to the treatment, with complete remission in 4 (23%) and partial remission in 7 (41%) (median time: 9 months). Three patients progressed to end-stage renal disease (ESRD) on follow-up. Of the three patients, one (33%) had an initial response in proteinuria to MMF but did not respond after a relapse and subsequently progressed to ESRD and two (67%) other patients were nonresponsive to MMF from the start of the therapy.

Conclusion. Despite a small sample size and lack of a control arm, this study describes the effectiveness of MMF in treating C3G patients from Asia and forms a basis for future randomized trials.

Keywords: C3 glomerulopathy, mycophenolate mofetil, response
INTRODUCTION

Isolated C3 glomerular deposits are pathognomonic of C3 glomerulopathy (C3G) [1]. It includes two entities, namely dense deposit disease (DDD) and C3 glomerulonephritis (C3GN), differentiated by electron microscopy [1]. The presence of intense C3 staining without other immunoglobulin deposits in the glomerulus reflects the activation of the alternative complement pathway (AP). The origin of abnormal AP activation is either genetic mutations or autoantibodies involving complement regulating/activating genes, or both [2].

The uniqueness of C3G lies in its diversity of clinical presentation and pathogenesis. The treatment of C3G is yet not structured, probably due to the rarity of the disease and lack of large observational studies/randomized trials with complement blockade therapy. Treatment options include nonspecific, non-immunosuppressive treatment such as renin-angiotensin-aldosterone blockade, nonspecific immunosuppressive therapy such as steroids [3, 4], mycophenolate mofetil (MMF) and specific complement-targeted therapy like eculizumab. Limited experience suggests a role of MMF in C3G [5, 6]. We report our experience of MMF in the management of C3G.

MATERIALS AND METHODS

The present report is a retrospective analysis of C3G patients treated with MMF for at least 6 months and with a follow-up of at least 12 months in the Department of Nephrology and Pediatrics, Post Graduate Institute of Medical Education and Research, Chandigarh, India. We retrieved clinical, histological and serological workup (complement C3 and C4 levels) of these patients from the medical records. Complement C3 and C4 levels were measured using semi-automated nephelometer MININEPHPLUS. Glomerular filtration rate was estimated from serum creatinine using the Chronic Kidney Disease Epidemiology Collaboration equation (2009) in adults and the Modified Schwartz formula in children. The Institute Ethics Committee approved the study protocol.

Definitions

C3G was defined as glomerular pathology characterized by dominant C3 staining by immunofluorescence microscopy [5, 6]. DDD was defined as dense osmiophilic glomerular intramembranous deposits [5, 6]. C3GN was defined as C3G that lacked the deposits seen in DDD [7, 8]. Nephrotic syndrome was defined as proteinuria ≥3.5 g/day or ≥1.5 g/day along with serum albumin <2.5 g/dL, edema and hyperlipidemia [9]. Complete remission (CR) was defined as return of serum creatinine to previous baseline, plus reduction in proteinuria to <0.5 g/day or 0.5 g/g creatinine by urine protein:creatinine ratio (uPCR). Partial remission (PR) was defined as stable (<25%) or improved serum creatinine, but not to normal, plus ≥50% reduction in proteinuria to <3 g/day (or 3 g/g uPCR) [10].

Statistical analysis

Data were entered into an Excel datasheet, and all statistical analyses were done using SPSS Version 23.0. (IBM Corp., Armonk, NY, USA). Continuous variables were expressed as median with interquartile range (IQR) or mean (±SD), and categorical variables are expressed as percentages.

RESULTS

A total of 17 patients with C3G were treated with MMF. The median (IQR) age at presentation was 16 (11–22) years, with 5 children and 12 adults. The most common mode of presentation was nephrotic syndrome (88.20%), with median (IQR) serum creatinine and proteinuria of 0.80 (0.60–1.00) mg/dL and 3.70 (1.90–5.00) g/day at the presentation, respectively. Sixteen (94.11%) patients had microscopic hematuria. Membranoproliferative glomerulonephritis was the most common histological pattern (Table 1). C3 and C4 levels were low in 12 (70.58%) and 1 (5.88%) patient, respectively.

The detailed assessment for genetic variants of the alternative complement pathway proteins was not done in our patients. However, the first 10 out of 17 patients underwent serological evaluation for complement pathway abnormalities with methods as described previously [11]. All the 10 (100%) patients had low AP functional assay (<28%). Five (50%) out of 10 patients were positive for circulating antibodies to complement regulatory proteins. Of the 10 patients, 3 (Patient #1, #4 and #9) were positive for C3Nef, 2 (Patient #2 and #10) were positive for anti-factor H antibody and 1 (Patient #1) was positive for anti-factor B antibody. Low factor B level (<85 mg/mL) and factor H level (<225 mg/mL) were seen in one patient (Patient #1), who also had positive anti-factor B antibody and C3Nef. All the investigations mentioned above were done only at baseline. The mean dose of MMF was 1.65 (±0.56) g/day, and the median (IQR) duration of MMF therapy was 12 (8–24) months. All the patients received renin-angiotensin-aldosterone system inhibitors right from the diagnosis through the last follow-up.

The baseline clinical characteristics of the patients are mentioned in Table 1. Eleven (64.70%) patients received MMF for nonresponse to oral prednisolone therapy (1 mg/kg/day for 8 weeks), and 6 patients received MMF upfront along with prednisolone (1 mg/kg/day). Oral MMF was started at 1 g/day and increased to 2 g/day within 2 weeks in all adults and to 1.2 g/m² in children. CR, PR and nonresponse were seen in four (23%), seven (41%) and six (35%) patients, respectively, at the last follow-up visit of median (IQR) 24 (20–48) months. The median (IQR) time to any remission was 9 (6–14) months. Of the 11 patients who received MMF for steroid resistance, 8 (72.72%) patients achieved remission at the last follow-up, with CR in 2 (18.18%) and PR in 6 (54.54%) patients, respectively. The remission rate

| Variable                           | Result         |
|------------------------------------|----------------|
| Gender (female, male)              | 7, 10          |
| Age at biopsy, median (IQR), years | 16 (11–22)     |
| Clinical presentation              |                |
| Nephrotic syndrome (n)             | 13             |
| Acute kidney injury or nephrotic syndrome (n) | 2          |
| Asymptomatic urinary abnormality (n) | 2            |
| Histology                          |                |
| C3GN, DDD                          | 9, 8           |
| Membranoproliferative glomerulonephritis (%) | 14 (82.35)     |
| Crescentic glomerulonephritis (%)  | 2 (11.76)      |
| Mesangial proliferative glomerulonephritis (%) | 1 (5.88)      |
| Serum creatinine, median (IQR), mg/dL | 0.8 (0.6–1.0)  |
| Estimated GFR, median (IQR), mL/min/1.73 m² | 106.9 (63.6–129.05) |
| Serum albumin, median (IQR), g/dL   | 2.6 (2–2.9)    |
| Proteinuria, median (IQR), g/day    | 3.7 (1.9–5.0)  |
| Hematuria (%)                      | 16 (94)        |
| Low C3 (%)                         | 12 (70)        |
| Low C4 (%)                         | 1 (5)          |

GFR, glomerular filtration rate; IQR, interquartile range; C3GN, C3 glomerulonephritis; DDD, dense deposit disease.
with 8 (80%) out of 11 patients with C3Nef-positive C3GN as compared with C3GN (62.5%). Forty percent of the patients with cir-

The most common clinical presentation in these patients was cyclophosphamide and 20 without any immunosuppression. Thirty patients received MMF, and 67% of patients had remis-

DISCUSSION

In this article, we report on 17 Indian patients with C3G, treated with MMF. Two-thirds of the patients responded favorably to MMF therapy.

The pathogenesis of C3G is not uniform. It lies in aberrant AP activation [2]. Studies on DDD and C3GN have shown the presence of homosygzous genetic mutations involving complement regulatory protein, such as Factor H, Complement Factor H-related protein 5 [12, 13] and complement-activating proteins such as C3 and factor B [14]. AP dysregulation could also result from acquired antibodies that stabilize the C3 and/or C5 conver-

dation in its widespread use.

Among all nonspecific immunosuppressive therapies, MMF-based treatment is promising compared with others concerning clinical remission and renal survival [5, 6]. Rabasco et al. [5] also noted a trend toward better clinical response and lower rates of ESRD in patients with C3Nef positivity than those without, similar to another report in children with C3Nef-positive C3G who achieved remission with MMF, steroids and plasma therapy [22]. The mechanism behind the success of MMF is not precise. It could be related to its anti-proliferative effects to reduce B-cell production of antibodies.

The usefulness of MMF in treating C3G was shown recently in two studies from the USA [6] and Spain [5]. Avasare et al. [6] from the USA compared patients with C3G treated with MMF or other immunosuppressive therapy (cyclophosphamide, calci-

The heterogeneity in the modes of treatment of C3G is owing to the rarity of the disease and limited access to laboratories diagnosing the specific pathogenic pathway. The prognosis remains poor despite treatment with 10-year renal survival being <50% [17]. There are various nonspecific immunosuppress-
sive therapies that have shown a variable response in retrospective cohorts. Steroids, at high dose (1 mg/kg/day), alone or with another immunosuppressive agent, have been the standard therapy used in treating C3G by various centers across the world [3–5]. Eculizumab, a monoclonal C5 antibody, is a specific complement-targeted therapy used in C3G [19, 20]. In contrast to atypical hemolytic uremic syndrome, where eculizumab is an effective therapy, response rates in C3G patients are heterogeneous, probably due to fundamental differences in pathogene-

Supplementary data, Figure S1, respectively.

At 0, 3, 6, 12 months and at last visit is shown in Table 2 and Supplementary data, Figure S1, respectively.

Patient #9, who had not responded to MMF and prednisolone initially, was later (6 months of therapy) found positive for monoclonal proteins and cryoglobulin (2% plasma cells in bone marrow biopsy and negative Hepatitis C virus-polymerase chain reaction viral load) on re-evaluation and was subsequently treated with bortezomib-based chemotherapy. The patient responded with CR to bortezomib-based treatment. The individual trends in serum creatinine, serum albumin and proteinuria at 0, 3, 6, 12 months and at last visit is shown in Table 2 and Supplementary data, Figure S1, respectively.

Patient #3, #8 and #10 developed end-stage renal disease (ESRD) on follow-up. Patient #10, although having advanced re-

There was an initial response (CR) to MMF and prednis-

Only two (40%) out of five patients with circulating antibodies achieved a response at last follow-up. The trends in median (IQR) serum creatinine, serum albumin and proteinuria at various time points are shown in Figure 1.

Patient #9, who had not responded to MMF and prednisolone initially, was later (6 months of therapy) found positive for monoclonal proteins and cryoglobulin (2% plasma cells in bone marrow biopsy and negative Hepatitis C virus-polymerase chain reaction viral load) on re-evaluation and was subsequently treated with bortezomib-based chemotherapy. The patient responded with CR to bortezomib-based treatment. The individual trends in serum creatinine, serum albumin and proteinuria at 0, 3, 6, 12 months and at last visit is shown in Table 2 and Supplementary data, Figure S1, respectively.

Patient #3, #8 and #10 developed end-stage renal disease (ESRD) on follow-up. Patient #10, although having advanced re-

The pathogenesis of C3G is not uniform. It lies in aberrant AP activation [2]. Studies on DDD and C3GN have shown the presence of homosygzous genetic mutations involving complement regulatory protein, such as Factor H, Complement Factor H-related protein 5 [12, 13] and complement-activating proteins such as C3 and factor B [14]. AP dysregulation could also result from acquired antibodies that stabilize the C3 and/or C5 conver-

The heterogeneity in the modes of treatment of C3G is owing to the rarity of the disease and limited access to laboratories diagnosing the specific pathogenic pathway. The prognosis remains poor despite treatment with 10-year renal survival being <50% [17]. There are various nonspecific immunosuppress-
sive therapies that have shown a variable response in retrospective cohorts. Steroids, at high dose (1 mg/kg/day), alone or with another immunosuppressive agent, have been the standard therapy used in treating C3G by various centers across the world [3–5]. Eculizumab, a monoclonal C5 antibody, is a specific complement-targeted therapy used in C3G [19, 20]. In contrast to atypical hemolytic uremic syndrome, where eculizumab is an effective therapy, response rates in C3G patients are heterogeneous, probably due to fundamental differences in pathogene-

Among all nonspecific immunosuppressive therapies, MMF-based treatment is promising compared with others concerning clinical remission and renal survival [5, 6]. Rabasco et al. [5] also noted a trend toward better clinical response and lower rates of ESRD in patients with C3Nef positivity than those without, similar to another report in children with C3Nef-positive C3G who achieved remission with MMF, steroids and plasma therapy [22]. The mechanism behind the success of MMF is not precise. It could be related to its anti-proliferative effects to reduce B-cell production of antibodies.

The usefulness of MMF in treating C3G was shown recently in two studies from the USA [6] and Spain [5]. Avasare et al. [6] from the USA compared patients with C3G treated with MMF or other immunosuppressive therapy (cyclophosphamide, calci-

The most common clinical presentation in these patients was asymptomatic urinary abnormalities. The presence of both acquired antibodies and underlying genetic abnormality is also described in patients with C3G [15]. We have not performed a detailed etiological evaluation of genetic or acquired factors in all our patients. Similar to prior reports [17, 18], patients with DDD in the present study had lower C3 (87%) com-

FIGURE 1: Box and whisker plot showing trends in serum creatinine (mg/dL), serum albumin (g/dL) and proteinuria (g/day) (median with IQR) at 0, 3, 6, 12 months and last visit.
serum creatinine or developed ESRD. Clinical remission was achieved in 86% of the patients treated with MMF. Relapse of proteinuria occurred in 27.27% patients after reduction of MMF dose. Although retrospective in design, these studies support the finding that MMF, an immunomodulatory drug, might be beneficial in treating C3G. Similar to the US group, our patients were younger and included both DDD and C3GN, and similar to the Spanish group, the majority of our patients presented with nephrotic syndrome. A summary of the studies on MMF in C3G is shown in Table 3.

The primary limitation of this study stems from the lack of a control arm and evaluation of alternative pathway of complement dysregulation in all patients. Nevertheless, the strength of the study lies in adequate collection of patient follow-up data at repeated points. Although underpowered by its small sample size and design, our study is the first report of the clinical outcome of patients with C3G treated with MMF from Asia. To conclude, we found remission in two-thirds of the Indian C3G patients treated with MMF. Our results provide a basis for future randomized trials comparing MMF with other immunosuppressive therapy in C3G patients.

**SUPPLEMENTARY DATA**

Supplementary data are available at ckj online.

**FUNDING**

Dr Ritambhra Nada received funding from PGIMER, Intramural Grant.
CONFLICT OF INTEREST STATEMENT
The authors of this article have no conflict of interest to declare, and the results presented in this article have not been published previously in whole or part.

REFERENCES
1. Fakhouri F, Frémeaux-Bacchi V, Noël L-H et al. C3 glomerulopathy: a new classification. Nat Rev Nephrol 2010; 6: 494–499
2. Bomback AS, Appel GB. Pathogenesis of the C3 glomerulopathies and reclassification of MPGN. Nat Rev Nephrol 2012; 8: 634–642
3. Sethi S, Fervenza FC, Zhang Y et al. C3 glomerulonephritis: clinicopathological findings, complement abnormalities, glomerular proteomic profile, treatment, and follow-up. Kidney Int 2012; 82: 465–473
4. Tarshish P, Bernstein J, Tobin JN et al. Treatment of mesangiocapillary glomerulonephritis with alternate-day prednisone—a report of the International Study of Kidney Disease in Children. Pediatr Nephrol 1992; 6: 123–130
5. Rabasco C, Cavero T, Román E et al. Effectiveness of mycophenolate mofetil in C3 glomerulonephritis. Kidney Int 2015; 88: 1153–1160
6. Avasare RS, Canetta PA, Bomback AS et al. Mycophenolate mofetil in combination with steroids for treatment of C3 glomerulopathy: a case series. Clin J Am Soc Nephrol 2018; 13: 406–413
7. Pickerling MC, D’Agati VD, Nester CM et al. C3 glomerulopathy: consensus report. Kidney Int 2013; 84: 1079–1089
8. Viswanathan GK, Nada R, Kumar A. Clinico-pathologic spectrum of C3 glomerulopathy—an Indian experience. Diagn Pathol 2015; 10: 6.
9. Raja R, Nada R, Yadav AK et al. A prospective study of collapsing focal segmental glomerulosclerosis. Ren Fail 2016; 38: 894–898
10. Kidney Disease: Improving Global Outcomes (KDIGO) Glomerulonephritis Work Group. KDIGO clinical practice guideline for glomerulonephritis. Kidney Int 2012; 2: 139–274
11. Nada R, Kumar A, Agrawal P et al. Renal and pulmonary dense deposit disease presenting as pulmonary-renal syndrome. Kidney Int Rep 2018; 3: 755–761
12. Gale DP. The identification of CFHR5 nephropathy. J R Soc Med 2011; 104: 186–190
13. Licht C, Heinen S, Józsi M et al. Deletion of Lys224 in regulatory domain 4 of Factor H reveals a novel pathomechanism for dense deposit disease (MPGN II). Kidney Int 2006; 70: 42–50
14. Martinez-Barricarte R, Heurich M, Valdes-Cañedo F et al. Human C3 mutation reveals a mechanism of dense deposit disease pathogenesis and provides insights into complement activation and regulation. J Clin Invest 2010; 120: 3702–3712
15. Servais A, Noël LH, Roumenina LT et al. Acquired and genetic complement abnormalities play a critical role in dense deposit disease and other C3 glomerulopathies. Kidney Int 2012; 82: 454–464
16. Chen Q, Müller D, Rudolph B et al. Combined C3b and factor B autoantibodies and MPGN type II. N Engl J Med 2011; 365: 2340–2342
17. Medjeral-Thomas NR, O’Shaughnessy MM, O’Regan JA et al. C3 glomerulopathy: clinicopathologic features and predictors of outcome. Clin J Am Soc Nephrol 2014; 9: 46–53
18. Thomas S, Ranganathan D, Francis L et al. Current concepts in C3 glomerulopathy. Indian J Nephrol 2014; 24: 339–348
19. Bomback AS, Smith RJ, Barile GR et al. Eculizumab for dense deposit disease and C3 glomerulonephritis. Clin J Am Soc Nephrol 2012; 7: 748–756
20. McCaughan JA, O’Rourke DM, Courtney AE. Recurrent dense deposit disease after renal transplantation: an emerging role for complementary therapies. Am J Transplant 2012; 12: 1046–1051
21. Welte T, Arnold F, Kappes J et al. Treating C3 glomerulopathy with eculizumab. BMC Nephrol 2018; 19: 7
22. Höffner K, Michelfelder S, Pohl M. Successful therapy of C3NeF-positive C3 glomerulopathy with plasma therapy and immunosuppression. Pediatr Nephrol 2015; 30: 1951–1959